3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
29
Carboplatin
10
Surveys and Questionnaires
9
Paclitaxel
9
Trastuzumab
8
Nivolumab
8
Cisplatin
8
Taxes
7
Gemcitabine
7
Bevacizumab
6
Specimen Handling
5
Oxaliplatin
5
Irinotecan
5
Fluorouracil
5
Cetuximab
5
Biopsy
5
spartalizumab
4
Leucovorin
4
Ipilimumab
4
Docetaxel
4
Cyclophosphamide
4
tisotumab vedotin
3
fludarabine
3
durvalumab
3
atezolizumab
3
aldesleukin
3
X-Rays
3
Psychiatric Rehabilitation
3
Magnetic Resonance Spectroscopy
3
Interviews as Topic
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
AZD9833
×
Gastrointestinal
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled